WASHINGTON (dpa-AFX) - AbbVie Inc. (ABBV) Wednesday said the Food and Drug Administration (FDA) has approved Skyrizi for the treatment of ulcerative colitis.
The approval was based on two Phase 3 studies dubbed INSPIRE and COMMAND, in which primary endpoint of clinical remission was achieved along with endoscopic improvement, a key secondary endpoint.
Skyrizi is already approved in the U.S. for plaque psoriasis, psoriatic arthritis, and Crohn's disease.
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2024 AFX News
